Voya Investment Management LLC Has $14.63 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Voya Investment Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 4.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 685,473 shares of the biopharmaceutical company’s stock after buying an additional 26,637 shares during the period. Voya Investment Management LLC’s holdings in ACADIA Pharmaceuticals were worth $14,628,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Banque Transatlantique SA acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter worth $31,000. Quantbot Technologies LP acquired a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $52,000. GAMMA Investing LLC raised its stake in shares of ACADIA Pharmaceuticals by 25.8% in the 3rd quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 690 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of ACADIA Pharmaceuticals by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,465 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 884 shares in the last quarter. Finally, Quarry LP bought a new position in shares of ACADIA Pharmaceuticals during the first quarter worth about $158,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Trading Up 3.3%

Shares of NASDAQ ACAD opened at $28.06 on Tuesday. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.40 and a 12 month high of $28.26. The stock has a 50 day moving average of $24.01 and a 200-day moving average of $23.45. The company has a market capitalization of $4.75 billion, a P/E ratio of 18.10, a P/E/G ratio of 7.30 and a beta of 0.67.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.14 by $0.28. The firm had revenue of $278.63 million for the quarter, compared to the consensus estimate of $276.52 million. ACADIA Pharmaceuticals had a net margin of 24.94% and a return on equity of 14.61%. The company’s quarterly revenue was up 11.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.20 earnings per share. Analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

Insider Transactions at ACADIA Pharmaceuticals

In related news, Director James M. Daly sold 30,000 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $22.37, for a total value of $671,100.00. Following the completion of the sale, the director directly owned 4,041 shares in the company, valued at $90,397.17. The trade was a 88.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider James Kihara sold 4,084 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total value of $96,749.96. Following the transaction, the insider owned 25,058 shares in the company, valued at $593,624.02. The trade was a 14.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 44,346 shares of company stock worth $1,010,957 over the last quarter. Company insiders own 28.30% of the company’s stock.

Wall Street Analyst Weigh In

ACAD has been the subject of several research reports. TD Cowen raised their price target on shares of ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, September 11th. Weiss Ratings restated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, December 15th. Wall Street Zen upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Cowen reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 11th. Finally, Royal Bank Of Canada lowered their target price on shares of ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating on the stock in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $29.95.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.